Abstract: The use of interleukin-11 to prevent, to ameliorate, and to treat an immune-mediated disease in a mammal in need of such treatment is disclosed.

Abstract: The present invention relates to methods and compositions for the diagnosis and treatment of hematological disorders, including, but not limited to, apalstic anemia, hemophilia, sickle cell anemia, thalassisemia, blood loss and other blood disorders, e.g., blood diorders related to bone marrow irradiation or chemotherapy treatment or renal failure. The invention further provides methods for identifying a compound capable of treating a hematological disorder. The invention also provides methods for identifying a compound capable of modulating a hematopoietic cell activity. Yet further, the invention provides a method for modulating a hematopoietic cell activity. In addition, the invention provides a method for treating a subject having a hematological disorder characterized by aberrant 2777 polypeptide activity or aberrant 2777 nucleic acid expression.

Abstract: The invention provides isolated nucleic acids molecules, designated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 and 65577 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 gene has been introduced or disrupted. The invention still further provides isolated 27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 proteins, fusion proteins, antigenic peptides and anti-27877, 18080, 14081, 32140, 50352, 16658, 14223, 16002, 50566, 65552 or 65577 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: The invention provides isolated nucleic acids molecules, designated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 and 8843 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 gene has been introduced or disrupted. The invention still further provides isolated 26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 proteins, fusion proteins, antigenic peptides and anti-26199, 33530, 33949, 47148, 50226, 58764, 62113, 32144, 32235, 23565, 13305, 14911, 86216, 25206 or 8843 antibodies.

Abstract: The invention provides isolated nucleic acids molecules, designated 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27875, 22025, 27420, 16319, 55092 and 10218 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 27875, 22025, 27420, 16319, 55092 and 10218 gene has been introduced or disrupted. The invention still further provides isolated 27875, 22025, 27420, 17906, 16319, 55092 or 10218 proteins, fusion proteins, antigenic peptides and anti-27875, 22025, 27420, 17906, 16319, 55092 or 10218 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: The present invention relates to methods for the diagnosis and treatment of hematological disorders. Specifically, the present invention identifies the differential expression of 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137, 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 and 13249 genes in tissues relating to hematological disorders sensation, relative to their expression in normal, or non-hematological disorders disease states, and/or in response to manipulations relevant to hematological disorders. The present invention describes methods for the diagnostic evaluation and prognosis of various hematological disorders, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating hematological disorders.

Abstract: The invention provides isolated nucleic acids molecules, designated 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 nucleic acid molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 gene has been introduced or disrupted. The invention still further provides isolated 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 proteins, fusion proteins, antigenic peptides and anti-18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 or 26908 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: Isolated nucleic acids molecules, designated 69039 nucleic acid molecules, which encode novel Na+/Ca2+ exchanger members, are disclosed. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 69039 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 69039 gene has been introduced or disrupted. Isolated 69039 proteins, fusion proteins, antigenic peptides and anti-69039 antibodies are also disclosed. The invention further provides methods of treating, preventing and diagnosing hematopoietic and neurological disorders.

Abstract: The present invention relates to methods for the diagnosis and treatment of hematological disorders. Specifically, the present invention identifies the differential expression of 252, 304, 1980, 14717, 9941, 19310 OR 17832 genes in tissues relating to hematological disorders sensation, relative to their expression in normal, or non-hematological disorders disease states, and/or in response to manipulations relevant to hematological disorders. The present invention describes methods for the diagnostic evaluation and prognosis of various hematological disorders, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating hematological disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of hematological disorders.

Abstract: The invention provides isolated nucleic acids molecules, designated 18080 nucleic acid molecules, which encode serine carboxypeptidase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18080 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18080 gene has been introduced or disrupted. The invention still further provides isolated 18080 proteins, fusion proteins, antigenic peptides and anti-18080 antibodies. Diagnostic methods utilizing compositions of the invention are also provided. Methods utilizing compositions of the invention to treat, prevent or diagnose hematopoietic disorders, e.g., erythroid-associated disorders, are also provided.

Abstract: The present invention relates to methods for the diagnosis and treatment of hematological disorders. Specifically, the present invention identifies the differential expression of 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 genes in tissues relating to hematological disorders sensation, relative to their expression in normal, or non-hematological disorders disease states, and/or in response to manipulations relevant to hematological disorders. The present invention describes methods for the diagnostic evaluation and prognosis of various hematological disorders, and for the identification of subjects exhibiting a predisposition to such conditions. The invention also provides methods for identifying a compound capable of modulating hematological disorders. The present invention also provides methods for the identification and therapeutic use of compounds as treatments of hematological disorders.

Abstract: The invention provides isolated nucleic acids molecules, designated 7118 nucleic acid molecules, which encode novel arginine N-methyltransferase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 7118 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 7118 gene has been introduced or disrupted. The invention still further provides isolated 7118 proteins, fusion proteins, antigenic peptides and anti-7118 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: The invention provides isolated nucleic acids molecules, designated 21132 nucleic acid molecules, which encode novel GPCR family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 21132 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 21132 gene has been introduced or disrupted. The invention still further provides isolated 21132 proteins, fusion proteins, antigenic peptides and anti-21132 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: The present invention relates to methods and compositions for the diagnosis and treatment of hematological disorders, including, but not limited to, apalstic anemia, hemophilia, sickle cell anemia, thalassisemia, blood loss and other blood disorders, e.g., blood diorders related to bone marrow irradiation or chemotherapy treatment or renal failure. The invention further provides methods for identifying a compound capable of treating a hematological disorder. The invention also provides methods for identifying a compound capable of modulating a hematopoietic cell activity. Yet further, the invention provides a method for modulating a hematopoietic cell activity. In addition, the invention provides a method for treating a subject having a hematological disorder characterized by aberrant 16319 polypeptide activity or aberrant 16319 nucleic acid expression.

Abstract: The present invention relates to methods and compositions for the diagnosis and treatment of hematological disorders, including, but not limited to, apalstic anemia, hemophilia, sickle cell anemia, thalassisemia, blood loss and other blood disorders, e.g., blood diorders related to bone marrow irradiation or chemotherapy treatment or renal failure. The invention further provides methods for identifying a compound capable of treating a hematological disorder. The invention also provides methods for identifying a compound capable of modulating a hematopoietic cell activity. Yet further, the invention provides a method for modulating a hematopoietic cell activity. In addition, the invention provides a method for treating a subject having a hematological disorder characterized by aberrant 2777 polypeptide activity or aberrant 2777 nucleic acid expression.

Abstract: The invention provides isolated nucleic acids molecules, designated 18636 nucleic acid molecules, which encode novel G protein coupled receptor family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 18636 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 18636 gene has been introduced or disrupted. The invention still further provides isolated 18636 proteins, fusion proteins, antigenic peptides and anti-18636 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: The invention provides isolated nucleic acids molecules, designated 6299 nucleic acid molecules, which encode novel zinc carboxypeptidase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 6299 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 6299 gene has been introduced or disrupted. The invention still further provides isolated 6299 proteins, fusion proteins, antigenic peptides and anti-6299 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: The invention provides isolated nucleic acids molecules, designated 23565 nucleic acid molecules, which encode novel zinc carboxypeptidase members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 23565 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 23565 gene has been introduced or disrupted. The invention still further provides isolated 23565 proteins, fusion proteins, antigenic peptides and anti-23565 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

Abstract: The invention provides isolated nucleic acids molecules, designated 27877 nucleic acid molecules, which encode a novel phospholipase. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 27877 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a 27877 gene has been introduced or disrupted. The invention still further provides isolated 27877 proteins, fusion proteins, antigenic peptides and anti-27877 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

Abstract: The present technique selectively handles image data, which is decomposed into a plurality of resolution levels. The image data may be retrieved in order of progressively higher resolution levels for display in a viewport, which may have a viewport resolution that is higher or lower than a desired one of the resolution levels. Initially, the image data may be displayed in the viewport at a relatively lower one of the plurality of resolution levels. As a user desires higher resolution displays of all or part of the image, one or more of the progressively higher resolution levels may be retrieved and scaled to fit the viewport. Accordingly, the present technique handles the data more efficiently by accessing the image data in blocks corresponding to the plurality of resolution levels, rather than accessing the entirety of the image data. A scaling threshold also can be used to signal the need for a next higher level of the plurality of resolution levels.